Sept

11

2025

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

Aug

14

2025

Denovo to Participate in Upcoming Investor Events

Jun

23

2025

Denovo Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan

Jun

06

2025

Denovo Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

Apr

03

2024

Denovo Announces a Major Breakthrough in Treatment Resistant Depression with Precision Medicine